GSK PLC Sponsored ADR $GSK Shares Acquired by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. increased its holdings in GSK PLC by 21.9% in Q1, owning over 1.25 million shares valued at approximately $48.5 million.
• GSK reported earnings of $1.23 per share for the last quarter, exceeding estimates and reflecting a 1.3% year-over-year revenue increase.
• The company declared a quarterly dividend of $0.4206 per share, representing an annualized yield of 4.3%, amidst a current payout ratio of 79.17%.

Russell Investments Group Ltd. grew its position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 21.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,251,700 shares of the pharmaceutical company's stock after acquiring an additional 224,860 shares during the quarter. Russell Investments Group Ltd. owned about 0.06% of GSK worth $48,491,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of GSK. HHM Wealth Advisors LLC boosted its holdings in GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC purchased a new stake in shares of GSK in the first quarter valued at approximately $31,000. Richardson Financial Services Inc. grew its holdings in GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares during the period. Olde Wealth Management LLC purchased a new position in GSK in the first quarter worth $36,000. Finally, Cary Street Partners Investment Advisory LLC raised its position in GSK by 525.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Price Performance

GSK traded down $0.27 during midday trading on Monday, reaching $39.09. 1,570,136 shares of the company's stock were exchanged, compared to its average volume of 5,200,675. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The stock has a market capitalization of $79.66 billion, a PE ratio of 18.09, a P/E/G ratio of 1.71 and a beta of 0.51. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The business's 50-day moving average price is $38.50 and its 200 day moving average price is $37.99.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter in the previous year, the company posted $0.43 EPS. The firm's revenue for the quarter was up 1.3% on a year-over-year basis. As a group, equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be issued a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Friday, August 15th. GSK's payout ratio is presently 77.78%.

Analyst Ratings Changes

GSK has been the topic of several research analyst reports. Berenberg Bank restated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, GSK currently has an average rating of "Hold" and an average price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.